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Background: Lynch syndrome is the most common genetic predisposition for hereditary cancer but
remains underdiagnosed. Large prospective observational studies have recently increased understanding
of the effectiveness of colonoscopic surveillance and the heterogeneity of cancer risk between genotypes.
The need for gene- and gender-specific guidelines has been acknowledged.
Methods: The European Hereditary Tumour Group (EHTG) and European Society of Coloproctology
(ESCP) developed a multidisciplinary working group consisting of surgeons, clinical and molecular
geneticists, pathologists, epidemiologists, gastroenterologists, and patient representation to conduct a
graded evidence review. The previous Mallorca guideline format was used to revise the clinical guidance.
Consensus for the guidance statements was acquired by three Delphi voting rounds.
Results: Recommendations for clinical and molecular identification of Lynch syndrome, surgical and
endoscopic management of Lynch syndrome-associated colorectal cancer, and preventive measures for
cancer were produced. The emphasis was on surgical and gastroenterological aspects of the cancer
spectrum. Manchester consensus guidelines for gynaecological management were endorsed. Executive
and layperson summaries were provided.
Conclusion: The recommendations from the EHTG and ESCP for identification of patients with Lynch
syndrome, colorectal surveillance, surgical management of colorectal cancer, lifestyle and chemopreven-
tion in Lynch syndrome that reached a consensus (at least 80 per cent) are presented.
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Definitions used in these guidelines
• Consensus: at least 80 per cent agreement
• Majority: 50–79 per cent agreement
• Subtotal colectomy: anastomosis is ileosigmoidal
• Total colectomy: anastomosis is ileorectal
• Extended surgery: refers either to subtotal colectomy
with ileosigmoidal anastomosis or total colectomy with
ileorectal anastomosis, when used to replace an oper-
ation that would be oncological standard practice for
a sporadic colorectal cancer, because of a pathogenic
germline variant
• Amsterdam criteria: these criteria were introduced
for uniform classification based on family history and
require at least three affected members on the same
side of the family in two or more generations, with one
being a first-degree relative of the other two and at least
one individual diagnosed before 50 years of age. The
Amsterdam I criteria apply to families with three or
more colorectal cancers, and the Amsterdam II criteria
also include extracolonic tumours: endometrial cancer,
cancer of the upper urinary tract and cancer of the small
bowel
• Carrier: a person with a germline path_MMR variant
• Lynch syndrome (LS): the dominantly inherited cancer
syndrome caused by the presence of a pathogenic mis-
match repair gene variant
• Revised Bethesda guidelines: guidance developed for
testing colorectal tumours for microsatellite instability
(MSI), when: colorectal or uterine cancer is diagnosed
in a patient who is less than 50 years of age; syn-
chronous, metachronous colorectal, or other hereditary
non-polyposis colorectal cancer (HNPCC)-associated
tumours (regardless of age) are present; colorectal
cancer with MSI-high is diagnosed in a patient who
is aged less than 60 years; colorectal cancer is diag-
nosed in one or more first-degree relatives with an
HNPCC-related tumour, with one of the cancers being
diagnosed under age 50 years; colorectal cancer is diag-
nosed in two or more first- or second-degree relatives
with HNPCC-related tumours, regardless of age
• Path_MMR: the pathogenic (disease-causing) variants of
the specified mismatch repair (MMR) gene associated
with cancer, including all structural or epigenetic vari-
ants of these
Executive summary of recommendations
Recommendations for the identification of patients with
Lynch syndrome (LS), colorectal surveillance, surgical
management of colorectal cancer, lifestyle and chemopre-
vention that reached a consensus (at least 80 per cent)
by a combined expert working group from the Euro-
pean Hereditary Tumour Group (EHTG; former Mal-
lorca Group) and the European Society of Coloproctol-
ogy (ESCP) are presented in Table 1. In addition, there was
agreement to endorse theManchester consensus statement
for gynaecological cancer in LS1. The summary of recom-
mendations for healthcare professionals is as follows.
General information
• LS is caused by inherited malfunction in one of the
four MMR genes named MLH1, MSH2, MSH6 and
PMS2. The malfunctioning variants are referred to as
path_MLH1, path_MSH2, path_MSH6 and path_PMS2.
People carrying inherited path_MMR or inherited epi-
genetically silenced variants of these genes are referred
to as carriers.
• Carriers have an increased risk of developing colorectal,
endometrial, ovarian, urinary tract, prostate and other
cancers, depending on which gene is malfunctioning.
Therefore, consideration to the responsible gene and
gender should be given where a pathogenic variant has
been identified.
• The average risk for cancer stratified by gene, organ,
gender and age is available at http://www.PLSD.eu.
This resource allows personalized genetic counselling to
support decision-making.
• The guidelines presented here are designed to empower
patients and clinicians to enable informed and individu-
alized decision-making; the authors recognize that there
is no universal approach to the care of those who carry
path_MMR and have LS, and therefore personalized care
is critical.
Identification of carriers
• All colorectal and endometrial cancer should be tested
for evidence of MMR deficiency to screen for LS. If
not limited by resources, all those with colorectal or
endometrial cancer can undergo direct germline testing
for path_MMR.
• The established clinical criteriamay be used for selecting
people without cancer to be genetically tested.
Surveillance for colorectal cancer
• Colonoscopy is recommended every 2 or 3 years for
path_MLH1, path_MSH2 and path_MSH6 carriers,
unless they have had colorectal cancer before, after
which biennial colonoscopy is recommended.
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Table 1 Recommendations that achieved consensus based on GRADE
Strength of
recommendation
% of voters
agreeing
Identification of LS
Amsterdam criteria and/or revised Bethesda criteria are not sufficient to guide tumour testing owing to low
sensitivity in detection of patients with LS
Strong* 86
All colorectal cancers should be tested by MMR (MLH1, MSH2, MSH6, PMS2) immunohistochemistry or
MSI testing (followed by possible MLH1 hypermethylation testing) to screen for LS
Strong* 91
Immunohistochemistry performed on preoperative colorectal cancer biopsies is at least as accurate as that
performed on resection specimens
Strong* 81
Colorectal surveillance
For path_MLH1, path_MSH2 and path_MSH6 carriers, 2- or 3-yearly colonoscopic surveillance is
recommended‡
Strong* 75
For path_PMS2 carriers, colonoscopic surveillance should be performed to reduce mortality and incidence
of colorectal cancer
Strong* 82
For path_PMS2 carriers, 5-yearly surveillance may be considered Weak† 80
For patients with LS with a history of CRC and segmental colectomy, biennial colonoscopies should be
performed
Strong* 88
For patients with LS with a history of CRC and segmental colectomy, biennial rectosigmoidoscopies should
be performed
Strong* 88
There is no evidence at the moment to support different surveillance colonoscopy intervals for men and
women
Strong* 100
Chromoendoscopy is equivalent to high-definition white-light endoscopy in specialist centres. It may be an
adjunct to be considered in the absence of high-definition endoscopy or in centres with lower adenoma
detection rates
Weak† 92
If bowel preparation is not entirely adequate, a repeat procedure at 1 year is recommended. If the bowel
preparation is completely inadequate or the examination incomplete, an immediate repeat colorectal
surveillance procedure should be requested (within next 6weeks)
Weak, based on
very low-quality
evidence (expert
opinion)
85
Age at onset of surveillance colonoscopy should be stratified according to genotype Strong* 100
For path_MLH1 or path_MSH2 carriers, surveillance colonoscopies should be initiated at the age of 25 years Moderate† 94
For path_MSH6 or path_PMS2 carriers, surveillance colonoscopies should be initiated at the age of 35 years Moderate† 93
Age at onset of surveillance should not be stratified by gender Moderate* 88
Surgical management of colorectal cancer
For a path_MLH1 or path_MSH2 carrier with a first colonic cancer, extended surgery with
ileosigmoidal/ileorectal anastomosis is preferable to standard resection to reduce the risk of
metachronous CRC
Strong* 82
For a path_MSH6 or path_PMS2 carrier with a first colonic cancer, standard/segmental colonic resection
should be offered
Weak* 80
For a path_MMR carrier with a metachronous colonic cancer, the surgical treatment can be extended
surgery with ileorectal/ileosigmoidal anastomosis.
Weak, based on
very low-quality
evidence
93
A decision on extended colorectal surgery for CRC should not be based on dMMR immunohistochemistry
(loss of MLH1, MSH2, MSH6 or PMS2) and BRAF staining/MLH1 hypermethylation from the preoperative
endoscopic biopsy only
Strong* 94
For a path_MMR carrier, the surgical treatment of a primary rectal cancer (occurring as the first colorectal
cancer) should be standard resection (anterior resection or APR)
Strong* 92
In a young path_MMR carrier with a rectal cancer and a synchronous neoplasia or a personal preference,
extended surgery can be considered
Weak, based on
very low-quality
evidence
86
Ileoanal pouch surgery (in agreement with ECCO guidelines for pouch surgery in ulcerative colitis) should be
performed in highly specialized colorectal surgical units
Moderate† 92
For endoscopically non-removable polyps with advanced histology, an oncological approach is
recommended, as for gene-specific treatment for carcinoma
Strong* 93
Prophylactic colorectal surgery in the absence of neoplastic lesions in the colorectum is not recommended
for path_MMR carriers based on their pathogenic variant-related risk only
Strong* 97
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Table 1 Continued
Strength of
recommendation
% of voters
agreeing
Lifestyle and chemoprevention
Path_MMR carriers should be advised that smoking increases the risk of colorectal cancer Weak† 100
Path_MMR carriers should be advised that obesity increases the risk of colorectal cancer Weak† 100
Path_MMR carriers should be advised that physical activity reduces the risk of colorectal cancer Weak† 90
Path_MMR carriers should be advised that alcohol consumption increases the risk of colorectal cancer Weak† 82
Path_MMR carriers should be advised that there is a high probability that daily aspirin will reduce cancer risk Weak# 90
Patients with path_MMR should be advised that there is a high probability that daily aspirin will reduce their
cancer risk
Weak* 100
The recommended aspirin dose should be a minimum of 75–100mg daily. This dose should be increased for
people with above-average body mass
Weak† 93
*Based on moderate-quality evidence; †based on low-quality evidence. ‡Consensus not reached between 2- and 3-year interval. GRADE, Grading
of Recommendations, Assessment, Development and Evaluation; LS, Lynch syndrome; MMR, mismatch repair; MSI, microsatellite instability; CRC,
colorectal cancer; dMMR, deficient mismatch repair; APR, abdominoperineal resection; ECCO, European CanCer Organisation.
Table 2 Overview of chromoendoscopy studies in Lynch syndrome
Reference Study outcomes
Brown et al.24 CE yielded more people with at least one neoplastic lesion (OR 1⋅53, 95 per cent c.i. 1⋅31 to 1⋅79). However, the authors felt the
evidence base was too small
Kamin´ski et al.25 The study strongly recommended the routine use of high-definition pancolonic CE in patients with known or suspected LS
(conventional CE, NBI, i-SCAN), but acknowledged the low-quality evidence
Lecomte et al.26 A small series reported that CE improved the adenoma detection rate in tandem colonoscopy studies
Stoffel et al.27 Patients underwent white-light colonoscopy and were then randomized to CE versus intensive inspection (withdrawal time of at
least 20min). CE was superior to standard white-light examination but not significantly different from intensive inspection
Rahmi et al.28 Patients underwent tandem colonoscopy with white light then CE. CE was superior, identifying 32 of 78 patients with one or more
adenomas versus 18 of 78 (P<0⋅001) and an additional adenoma in 24 of 78 (31%).
van Rijn et al.29 A 20% adenoma miss rate in average-risk cohorts was reported in a systematic review of tandem white-light/CE studies
East et al.30 The authors reported a significantly increased adenoma detection rate with NBI. However, there was no randomization of the order
in which NBI and white-light colonoscopy were undertaken in this study, which is a major methodological criticism
Bisschops et al.31 An increased adenoma detection rate was reported with the use of i-SCAN versus high-definition white-light colonoscopy in 61
patients with LS. Patients were randomized to i-SCAN or white light first
Hüneburg et al.32 In a comparison of white light with CE and virtual chromoendoscopy, CE was found to be significantly better than NBI and
standard white-light colonoscopy
Rondagh et al.33 Findings in patients with and without LS were compared. LS adenomas were more likely to be non-polypoid (43 versus 17%; OR
3⋅6, P<0⋅001). This was particularly so for those in the proximal colon (58 versus 16%; OR 6⋅93, P<0⋅001). Advanced histology
was more likely to be found in non-polypoid adenomas in patients with LS than those without (4 of 5 versus 5 of 12). Serrated
lesions were more likely to be non-polypoid in LS (49 versus 20%; OR 3⋅57, P<0⋅001)
CE, chromoendoscopy; OR, odds ratio; NBI, narrow-band imaging; i-SCAN, postprocessing software filter technology; LS, Lynch syndrome.
• Path_PMS2 carriers may be considered for 5-yearly
colonoscopy.
• Colonoscopy surveillance is recommended starting at
age 25 years for path_MLH1 and path_MSH2 carriers,
and at age 35 years for path_MSH6 and path_PMS2
carriers.
• The recommended surveillance for colorectal cancer
does not differ between men and women.
Surveillance, management and prevention
of gynaecological cancer
• The Manchester International Consensus Group1
recommendations for the surveillance, management
and prevention of gynaecological cancers in LS are
endorsed.
Surgical management of colorectal cancer
• Extended surgery is recommended for path_MLH1 and
path_MSH2 carriers at the time of first diagnosis of a
colonic cancer.
• Removing part of the colon or rectum in the absence
of cancer or endoscopically non-removable polyps is not
generally recommended for path_MSH6 and path_PMS2
carriers.
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Fig. 1 Summary of core content of the recommendations
Identification of Lynch syndrome
 MMR IHC or MSI testing for all CRC
 (followed by possible MLH1 hypermethylation testing)
Lifestyle and chemoprevention
 Increase CRC risk
 Smoking, obesity, alocohol consumption
 Reduce CRC risk
 Physical activity and daily acetylsalicylate
 of at least 75 mg
Recommendations from EHTG
and ESCP for Lynch syndrome
based on gene and gender
Surgical management of CRC
 Extended surgery for path_MLH1
 and path_MSH2 carriers at the
 time of first diagnosis of colonic cancer
CRC surveillance
 Intveral
 Every 2–3 years for path_MLH1, path_MSH2
 and path_MSH6 carriers, and 5-yearly for path_PMS2 carriers
 Starting age
 At age 25 years for path_MLH1 and path_MSH2
 carriers. At age 35 years for path_MSH6 and path_PMS2 carriers
 Gender
 No difference between men and women
MMR, mismatch repair; IHC, immunohistochemical; MSI, microsatellite instability; CRC, colorectal cancer; EHTG, European Hereditary Tumour
Group; ESCP, European Society of Coloproctology.
Lifestyle and chemoprevention
• Smoking and obesity increase the risk of colorectal can-
cer in carriers.
• Alcohol consumption increases the risk of colorectal
cancer in carriers.
• Physical activity reduces colorectal cancer risk in carri-
ers.
• Daily acetylsalicylic acid of at least 75mg reduces cancer
risk in carriers.
Recommendations for professionals have been summa-
rized in Fig. 1 and Table S1 (supporting information). Uni-
versal laboratory screening for upper urinary tract carcino-
mas to identify LS was approved by a majority (73 per cent)
but did not reach consensus. A summary of recommenda-
tions for patients (layperson summary) is presented in Table
S2 (supporting information).
Introduction
LS (OMIM #120435) is the most common dominantly
inherited cancer syndrome but is often not recognized2,3.
The prevalence of path_MMR carriers has been estimated
to be around one in 300, that is 2⋅5 million people in
Europe alone4.
Carriers are at increased risk of developing cancers,
including colorectal, endometrial, ovarian, stomach,
pancreatic, small bowel, biliary tract, urinary tract, brain
and skin cancer. In LS, these cancers may occur much ear-
lier in life than their sporadic counterparts, but older age
of onset is not infrequent, and penetrance and expression
vary by gene and gender from very high to immeasurable.
The International Society for Gastrointestinal Hereditary
Tumours (InSiGHT), through the use of its international
database (http://insight-database.org/) and expertise, cat-
egorizes MMR gene variants as being pathogenic (class 5)
or likely to be pathogenic (class 4) (or as being of uncertain
significance, likely not pathogenic or not pathogenic). This
information can then be used to inform patient-centred
counselling in consultation with the Prospective Lynch
Syndrome Database (PLSD) (http://www.plsd.eu). Poten-
tially modifiable factors include acetylsalicylic acid (aspirin)
prophylaxis and lifestyle. Typically, LS-associated cancers
have significantly better prognoses than sporadic cancers
affecting the same organs, reflecting biological differences,
including the marked immune responses that characterize
LS cancers5. Patients with LS who are within cancer
surveillance programmes benefit from a stage shift and
earlier cancer diagnosis and usually survive their first
cancers. Despite surveillance, those with LS can go on
to develop metachronous cancers, with service planning
implications6.
Carriers are identified by demonstration of a class 5 or
4 germline path_MMR variant. HNPCC refers to a family
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Fig. 2 Clinical classification of hereditary non-polyposis colo-
rectal cancer and causal genes7
Dominantly inherited
non-polyposis
colorectal cancer
(HNPCC)
MMR-proficientMMR-deficient
Lynch-like syndrome
(if not detectable
genetic cause)
Lynch syndrome
(MMR pathway)
Other genes
MLH1, MSH2, MSH6,
PMS2
HNPCC, hereditary non-polyposis colorectal cancer; MMR, mismatch
repair.
history indicating dominantly inherited colorectal cancer,
which was later divided to specify several distinct, inher-
ited, cancer syndromes that include colorectal cancer and
other cancers (Fig. 2)7. Previously published guidelines8,9,
for clinical management of LS were based on retrospective
studies and made uniform management recommendations,
regardless of which gene was involved.
Methods
Guideline group
In 2007, a group of European experts (theMallorca Group)
published guidelines for the clinical management of LS10
that were revised in 20138. The present second revi-
sion was conducted by a combined expert working group
from the EHTG (former Mallorca Group) and ESCP, and
was based on previously selected clinical questions. The
group consisted of surgeons, clinical and molecular geneti-
cists, pathologists, epidemiologists, gastroenterologists and
a patient representative. If a particular specialty was not
represented, specialists outside the group were consulted.
It was decided that the update format of the manuscript
would be via a continuous update process to be undertaken
by the EHTG (living guidance).
Scope of updated guidelines
This update is based on the results from new prospective
studies that reported the average risk of cancer in carriers
by organ, by age, by gene and by gender. It covers the
screening, diagnosis and management of LS, and is tar-
geted for patients with this condition. Its aim is to gather
the most up-to-date evidence on the management of LS.
Furthermore, this guideline addresses the clinical questions
raised in previous versions, and updates recommendations
for the clinical management of carriers. Specifically, the
guideline details the treatment and prevention of cancers
based on gene and gender, and identifies areas requiring
more research. This document is directed to patients of
both genders and all age groups in which the diagnosis of
LS is suspected or confirmed. The recommendations are
directed to all patients with the condition, irrespective of
severity or co-morbidities.
Literature search
A PICO (Patients, Intervention, Comparison, Outcome)
model structure was created for each area of interest,
based on previously published template questions8. A
systematic literature search was performed using the
PubMed database and the Cochrane Database of System-
atic Reviews, and manual searches of relevant articles up
until November 2018. The following Medical Subject
Heading (MeSH) terms were used: ‘hereditary nonpolypo-
sis colorectal cancer’[All Fields] OR ‘Lynch syndrome’[All
Fields]; 3893 articles were identified. The titles were
screened and relevant articles written in English were
reviewed, and the level of evidence was graded as high,
moderate, low or very low, according to GRADE (Grad-
ing of Recommendations, Assessment, Development and
Evaluation) criteria (http://www.gradeworkinggroup.org/)
(Table S3, supporting information).
Timeline and meetings
During the working group meetings (3 meetings and sev-
eral teleconferences), the outcomes of the literature search
were discussed in detail. PICOs are available inAppendix S1
(supporting information) and Delphi round results in Table
S4 (supporting information).
Suggestions for guidance statements emerging from the
literature review were formulated and tested through Del-
phi model-based voting rounds. The first Delphi round
took place as an online questionnaire on SurveyMonkey® (
https://www.surveymonkey.co.uk) in week 38 of 2018. The
stakeholders were identified from the membership of the
EHTG to provide multidisciplinary expertise. The state-
ments were thereby revised for a second Delphi round via
live voting which took place in week 39 of 2018, among
participants at the Third Annual Meeting of the EHTG
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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in Nice, France. The statements were revised again, and
a third Delphi round was conducted by SurveyMonkey®
with voting in weeks 32–34 of 2019, again amongmultidis-
ciplinary stakeholders identified by the EHTG. The most
recent results from the PLSD studies were disclosed to all
participants before voting, but were only published later11.
The threshold for reaching consensus in the Delphi votes
was set at 80 per cent.
The AGREE reporting checklist was used to guide the
reporting of the process (Appendix S1, supporting informa-
tion). An external review of the statements was undertaken
before the third Delphi round, focusing mainly on the lan-
guage of the statements communicating the strength of the
recommendation based on the quality of evidence.
Question 1: how can the identification of Lynch
syndrome be improved?
LS carcinomas of the large bowel are associated with a
highly cellular, medullary or mucinous appearance, with a
marked increase in the number of intratumoral and peritu-
moral lymphocytes, a pushing border with a low frequency
of budding and low stromal content. They have a lower rate
of nodal spread. Although these phenotypic features are in
keeping with aberrant MMR protein expression, they are
not specific for LS.
The clinical criteria for preselection of people for genetic
testing (Amsterdam II12 and revised Bethesda13 criteria) are
insensitive and lack specificity in identifying carriers (Table
S5, supporting information); testing of incident colorectal
cancer cases has been recommended for over a decade. In
parallel with the present work, a consensus guideline meet-
ing on gynaecological cancer in LS recommended screen-
ing for LS in patients with endometrial and ovarian cancer
(and also BRCA1/2 screening in ovarian cancer). Further-
more, identification of carriers provides the opportunity for
cascade testing of relatives, which has the benefit of identi-
fying healthy carriers. These approaches have been shown
to be cost-effective14,15.
Laboratory screening of patients with upper urinary tract
cancer to identify LS was agreed by a majority (73 per cent)
but did not reach consensus.
Conclusions and recommendations
• All colorectal cancers should be tested byMMR (MLH1,
MSH2, MSH6, PMS2) immunohistochemistry or MSI
testing (followed by possible MLH1 hypermethylation
testing) to screen for LS.
• Patients with endometrial or ovarian cancer should be
screened by immunohistochemistry or DNA testing as
described in the Manchester consensus statement.
Question 2: what is the optimal colorectal
surveillance protocol for Lynch syndrome?
Subquestion 1: should colonoscopic surveillance be
performed?
Data from largely observational studies conducted since
the 1990s have supported the role of colonoscopic surveil-
lance in patients with LS. Järvinen and colleagues16,17
reported on the outcomes of a cohort of patients with LS
who underwent colonoscopic surveillance and compared
them with a group who did not, and observed a 62 per cent
reduction in colorectal cancer in the surveillance group.
Similar observations were made in other studies18–20.
Altogether, colonoscopic surveillance seems to lead to a
60–72 per cent decrease in colorectal cancer mortality.
More recent data from prospective observational studies
have questioned the previously reported benefits in earlier
studies16,17,20 of comparative colorectal cancer incidence.
Specifically, nearly half of path_MLH1 and path_MSH2
carriers develop colorectal cancer under surveillance6,21–23,
and the benefits of colonoscopic surveillance are mainly
to improve survival by earlier detection compared with no
surveillance.
Conclusions and recommendations
• There was consensus agreement that for all path_MMR
carriers colonoscopic surveillance should be performed
to reduce mortality and incidence of colorectal cancer.
Subquestion 2: should chromoendoscopy/virtual
chromoendoscopy be performed?
Chromoendoscopy (CE) uses contrast dyes (usually indigo-
carmine) to highlight the mucosal surface contours and
enhance visualization. In virtual CE, filtering technology
is built into the colonoscope system, which alters the
white-light image to highlight mucosal surface architec-
ture and capillary pattern. Results with use of CE and
virtual CE are summarized in Table 224–33. These stud-
ies are largely methodologically flawed, which limits the
conclusions that can be drawn. CE may be equivalent to
high-quality white-light examination with prolonged with-
drawal. However, given the conflicting results of studies,
and themethodological flaws ofmost published studies, CE
may still be a helpful adjunct to be considered in colono-
scopic surveillance in LS.
Conclusions and recommendations
• Chromoendoscopy is equivalent to high-definition
white-light endoscopy in specialist centres. It may
be an adjunct to be considered in the absence of
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Table 3 Studies describing the cumulative incidence of colorectal cancer in patients with Lynch syndrome
70-year cumulative incidence (%)
Reference Gender MLH1 MSH2 MSH6 PMS2
Bonadona et al.38 Both 41 48 12
Dowty et al.36 Men 34 47
Women 36 37
ten Broeke et al.37 Men 13*
Women 12*
PLSD6 Men 53 42 18 10
Women 44 46 20 10
* Cumulative risk at 80 years. PLSD, Prospective Lynch Syndrome Database.
high-definition endoscopy or in centres with lower
adenoma detection rates.
Subquestion 3: what is the appropriate
colonoscopic surveillance interval?
In studies from the PLSD published by Møller and
colleagues21, the interval between last surveillance
colonoscopy and colorectal cancer was analysed. Of
145 colorectal cancers, 100 were diagnosed more 2 years
after the last colonoscopy (interval after colonoscopy range
0–125months). On the other hand, the high incidence
of colorectal cancers in the PLSD despite colonoscopic
surveillance was not due to the inclusion of a large cohort
of Finnish path_MLH1 carriers for whom a 2–3-year
interval between colonoscopies had been recommended34.
The cumulative incidence of colorectal cancer or stage
at detection did not differ between 1-yearly, 2-yearly and
2–3-yearly colonoscopic surveillance strategies in a study
of 2747 path_MLH1, path_MSH2 and path_MSH6 carriers
who were followed up for a total of 23 309 years by 16 327
colonoscopies23.
Gathering evidence suggests that carcinogenesis in
path_PMS2 is predominantly via the adenomatous
pathway35, and that the cancer risk is substantially lower
than that for other LS genotypes, especially under colono-
scopic surveillance6.
There is no reported substantial difference in life-
time incidence of colorectal cancer between that
estimated by retrospective segregation analyses over
three generations36–38 and that in the PLSD report6 on
the effects of colonoscopy in preventing colorectal cancer
as advocated by recent international guidelines (Table 3).
Conclusions and recommendations
• For path_MLH1, path_MSH2 and path_MSH6 carriers,
2- or 3-yearly colonoscopic surveillance is recommended
(consensus not reached between 2 and 3 years).
• For path_PMS2 carriers, 5-yearly surveillance may be
considered.
• For patients with LS with a history of colorectal cancer
and segmental or subtotal colectomy, biennial colono-
scopies should be performed.
• There is no evidence at the moment to support different
surveillance colonoscopy intervals for men and women.
• If bowel preparation is not entirely adequate, a repeat
procedure at 1 year is recommended.
• If the bowel preparation is completely inadequate or the
examination incomplete, an immediate repeat colorectal
surveillance procedure should be requested (within next
6weeks).
Subquestion 4: at what age should surveillance
colonoscopy be initiated?
A number of studies have confirmed that the risk of devel-
oping colorectal cancer before the age of 25 years is very
low (Table 4)6,8,21,22,37–48.
The risk of a path_PMS2 carrier developing can-
cer at young age is low, and the median age for
path_PMS2-related first colorectal cancers is 52 years47.
Based on PLSD studies, path_MSH6 carriers also have a
lower risk of early-onset cancer; the cumulative colorectal
cancer risk at age 40 years was 12 per cent for path_MLH1,
9 per cent for path_MSH2 and 0 per cent for path_MSH6.
There is no convincing evidence to show that the age of
onset is different between men and women.
Conclusions and recommendations
• For path_MLH1 or path_MSH2 carriers, surveillance
colonoscopies should be initiated at the age of 25 years.
• For path_MSH6 or path_PMS2 carriers, surveillance
colonoscopies should be initiated at the age of 35 years.
• Age at onset of surveillance should not be stratified by
gender.
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
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Table 4 Overview of studies about age and risk of developing colorectal cancer in Lynch syndrome
Reference Study outcomes
de Jong et al.39 Only two of 246 patients (0⋅8%) with LS developed CRC before the age of 20 years and another two between age 20 and
25 years
Hendriks et al.40
Quehenberger
et al.41
Hampel et al.42
Jenkins et al.43
These studies confirmed that the risk of developing CRC before the age of 25 years is very low
Vasen et al.8
Cairns et al.44
Rubenstein et al.45
These previous guidelines recommended starting surveillance colonoscopy at age 20–25 years.
Jenkins et al.46 This meta-analysis for path_MLH1 and path_MSH2 carriers questioned whether the initiation of surveillance colonoscopy was
justified before the age of 30 years
Giardiello et al.47 US multisociety task force guidelines recommended starting surveillance colonoscopy at 20–25 years (or 2–5 years younger
than youngest affected if aged <25 years), but to consider starting at 30 and 35 years for path_MSH6 and path_PMS2
carriers respectively
ten Broeke et al.37,48 The study described a series of 377 patients with path_PMS2 and the observed median age at first CRC was 52 (range 26–86)
years. The authors also noted gender differences in CRC risk. The cumulative risk in men aged <40, 40–49, 50–59 and
60–69 years was 1⋅3, 4⋅6, 7⋅1 and 18⋅8% respectively. The corresponding cumulative risks by age in women were 0⋅5, 0⋅9,
4⋅7 and 10⋅5%. It was recommended that starting colonoscopy surveillance could be deferred until age 30 years for both
genders.
ten Broeke et al. also published a large series of patients with path_PMS2, and reported only a 2–3 times increased cumulative
incidence of CRC under surveillance compared with the general population. This is about the same level of CRC risk as when
there is a positive family history of the disease but genetic testing for LS (and other hereditary CRC syndromes) proves
negative
Bonadona et al.38 This nationwide French study of patients with LS supports a genotype–phenotype correlation. There were no path_PMS2
carriers in this cohort. Overall, the cumulative CRC risk by 70 years was 38% in men and 31% women. When analysed by
genotype, the cumulative CRC risks were 46% for path_MLH1, 48% for path_MSH2 and 12% for path_MSH6. Median age at
diagnosis of CRC also varied by genotype: 45 (range 15–90) years for path_MLH1, 44 (16–95) years for path_MSH2 and 54
(24–85) years for path_MSH6
Møller et al.6,21,22 In the 2017 PLSD report addressing incidence and survival of first cancers in patients with LS undergoing surveillance, the
cumulative CRC incidence to age 70 years was 46% for path_MLH1, 35% for path_MSH2, 20% for path_MSH6 and 0% for
path_PMS2. Overall, when incidence was analysed by gender, no difference was observed between men and women. The
recent report (2018) from the PLSD described cancer risks and survival up to age 75 years, analysing the data both by gene
and gender. The cohort included 3119 patients with 24 475 observation years. The previously described
genotype-dependent penetrance was confirmed; the cumulative CRC risk to age 75 years by genotype was: 46% for
path_MLH1, 43% for path_MSH2, 15% for path_MSH6 and 0% for path_PMS2 (although there were only 124 path_PMS2
carriers in this cohort, so no firm conclusions could be drawn regarding this subgroup). Path_MSH6 has a lower risk of
early-onset cancer; the cumulative CRC risk at age 40 years was 12% for path_MLH1, 9% for path_MSH2 and 0% for
path_MSH6. There were no consistent gender differences for CRC within each genotype group
LS, Lynch syndrome; CRC, colorectal cancer; PLSD, Prospective Lynch Syndrome Database.
Question 3: what is the effectiveness
of surveillance for other cancers?
The individual cumulative risk of cancer in any organ for
the remaining lifetime of a patient with LSmay be obtained
by indicating their age, gender and genetic variant using
http://www.plsd.eu/. There is no demonstrated benefit of
surveillance for incidence or survival of gastric cancer,
small bowel cancer, pancreatic cancer, urinary tract cancer,
prostate cancer or breast cancer in path_MMR carriers
(Table 5)6,49–56.
Conclusions and recommendations
• Consensus was not achieved for the statement ‘Surveil-
lance for other cancers (than colorectal, endometrial and
ovarian) should not be offered’.
Question 4: what is the appropriate surgical
treatment for colorectal cancer?
The risk of metachronous colorectal cancer after primary
colonic cancer depends on which variant a carrier has and
on the extent of surgery performed in managing the pri-
mary colonic cancer (how much colon is left to be at risk).
There are no good data describing the risk of a second
colonic cancer by gene and treatment of first cancer. Ana-
lyses in the PLSD22 suggested that the risk of a second
colorectal cancer was determined stochastically: the risk
of a second cancer was not substantially different from
the risk of a first cancer by age, gene and gender. With-
out stratifying by gene and treatment of first colonic can-
cer (because numbers in the study did not allow substrata
for analysis), a PLSD study22 reported that the risk of
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Table 5 Studies describing cumulative risk and surveillance outcome for gastric, small bowel, pancreatic, urinary tract, prostate and
breast cancer in Lynch syndrome
Reference Study outcomes
Gastric
Møller et al.6 There is a relative increase in incidence of 8⋅9 for path_MLH1 and 9⋅7 for path_MSH2 carriers compared with the general
population
Park et al.49 Geographical differences may be significant, with this report from Korea showing a higher lifetime risk
Capelle et al.50 The Dutch Gastric Cancer Registry study revealed that the majority of gastric cancers in this patient population is of the
intestinal type (62%)
Renkonen-Sinisalo
et al.51
The study collected data on 73 mutation-positive patients with a mean age of 49 years. In this group, an upper endoscopy
for surveillance did not identify any neoplastic changes
Small bowel
Møller et al.6 There is a relative increase in incidence of this type of cancer of 64⋅7 for path_MLH1 carriers
ten Kate et al.52 The study reported distribution predominantly in the duodenum and jejunum
Saurin et al.53 The authors reported on 35 asymptomatic patients undergoing capsule endoscopy, which identified lesions in three patients.
Of these, one had a jejunal adenocarcinoma and two had adenomas with low-grade dysplasia
Haanstra et al.54 The authors examined the effect of video capsule endoscopy in the detection of small bowel neoplasia in 200 asymptomatic
patients. In this group, there were significant findings in two patients, who were diagnosed with adenocarcinoma (1
patient) and adenoma (1). An adenocarcinoma diagnosed 7months after a negative capsule endoscopy was considered a
missed lesion. Two years later, 155 of the initial 200 patients underwent a second video capsule endoscopy. Findings
leading to further endoscopies with gastroduodenoscopy or balloon-assisted endoscopy were seen in 11% of patients
but none proved to be neoplasia
Pancreatic
Møller et al.6 The relative risk of pancreatic cancer is 7⋅8 for path_MLH1 carriers
Canto et al.55 In this large study of screening in 354 patients at high risk of pancreatic cancer, a survival benefit was identified for patients
diagnosed during screening. This study used endoscopic ultrasonography, MRI and CT for screening. However, no
patients with LS were diagnosed with a tumour
Urinary tract
Møller et al.6 There is a relative increase in incidence of bladder cancer of 4⋅1 for path_MLH1 and 8⋅1 for path_MSH2 carriers. There is
also a relative increase in incidence of ureter and kidney cancer of 3⋅5 for path_MLH1 and 13⋅7 for path_MSH2 carriers
Myrhøj et al.56 The National Danish HNPCC registry assessed a strategy of screening with urinary cytology. In this study of 977 individuals,
including 263 with confirmed path_MMR variants, urine cytology had a sensitivity of 29%, with a specificity of 96%. Five
of 14 cancers that occurred were interval cancers not detected by screening
Prostate
Møller et al.6 There is a relative increase in incidence of this type of cancer of 3⋅2 for path_MSH2 carriers
IMPACT study (http://
impact.icr.ac.uk/)
The study is currently recruiting carriers of path_MLH1, path_MSH2 and path_MSH6, and those who have tested negative
for path_MLH1, path_MSH2 or path_MSH6 known to be present in their family. This study can be considered for patients
undergoing surveillance for LS
Breast
Møller et al.6 In the PLSD, there is a relative incidence of breast cancer of 1⋅3 for path_MLH1, 1⋅2 for path_MSH2 and 1⋅4 for path_MSH6
carriers. In this cohort, the confidence intervals all include 1 and it is not possible to confirm a significant increase in breast
cancer risk at this time
LS, Lynch syndrome; HNPCC, hereditary non-polyposis colorectal cancer; PLSD, Prospective Lynch Syndrome Database.
metachronous colorectal cancer by 70 years (starting from
40 years) after an earlier colonic cancer and despite reg-
ular colonoscopies was 36 (95 per cent c.i. 29 to 43⋅8)
per cent. The numbers were likely to be conservative esti-
mates for metachronous cancer, because a substantial pro-
portion of these patients were treated at specialized cen-
tres and will have had extended colonic surgery. Three
recent meta-analyses and several independent studies eval-
uated the risk of metachronous colorectal cancer after
colectomy for colonic cancer (Table 6)57–65. No studies
have reported the risk of a third colorectal cancer after
subsequent colonic cancer. However, third metachronous
colorectal cancers have been described, as has survival after
these subsequent cancers22. There are no studies address-
ing the more invasive surgical option of extending colorec-
tal surgery to a proctocolectomy at the occurrence of a
first or metachronous colonic or rectal cancer. It is essen-
tial to evaluate the role of extended surgery prospectively
and provide recommendations stratified by MMR gene in
order to reduce the incidence of metachronous colorectal
cancer occurring in path_MMR carriers.
Extended surgery, either subtotal colectomy with ileosig-
moidal anastomosis or total colectomy with ileorectal
anastomosis, for primary colonic cancer in path_MLH1
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Table 6 Studies describing surgical treatment for colorectal cancer in Lynch syndrome
Reference Study outcomes
Anele et al.57 This report included six studies involving 871 patients who met the inclusion criteria (705 had segmental colectomy and 166
extended colectomy). The weighted mean follow-up was 7⋅6 years. Patients with LS were four times more likely to develop
metachronous CRC after segmental colectomy than those who had extended resection, despite regular endoscopic
surveillance (1–2-yearly)
Heneghan et al.58 This review included eight studies and 948 patients (780 had segmental colectomy and 168 extended colectomy) followed up
for 8⋅9 years, but they did not exclude studies based on clinical criteria only for diagnosis of LS. The authors calculated the
risk of metachronous CRC to be 3⋅7 times higher after segmental colectomy than extended resection. There were limitations
regarding morbidity and mortality data in most of the original studies
Malik et al.59 This meta-analysis identified 1389 patients with LS and HNPCC followed up for a mean of 8⋅4 years, with a mean age at onset
of 45⋅5 years. A total of 1119 patients underwent segmental colectomies with an absolute risk of metachronous CRC of
22⋅4% at the end of follow-up. The 270 patients who underwent extended colectomies had a metachronous CRC risk of
4⋅7%. Segmental colectomy was significantly associated with an increased RR of metachronous CRC (RR 5⋅12, 95% c.i.
2⋅88 to 9⋅11), although no significant association with mortality was identified (RR 1⋅65, 0⋅90 to 3⋅02)
Renkonen-Sinisalo
et al.60
The authors compared the outcomes of 242 genetically confirmed LS carriers who underwent either STC (98) or segmental
colectomy (144), and were followed up for between 14⋅6 and 25 years. The cumulative risk of metachronous CRC after
segmental colectomy was 47% compared with 7% after STC+ ISA. Extended surgery also reduced the risk of subsequent
abdominal surgery compared with segmental resection (10⋅9 versus 54⋅1%), but there was no difference in CRC-specific
survival. However, the majority of patients were path_MLH1 carriers. For patients undergoing STC, 10–20 cm of sigmoid
was left and an ISA performed
Kim et al.61 The cumulative risk of metachronous CRC was reported to be 20⋅4% in 10-year follow-up after segmental colectomy
compared with 0% after extended surgery in this South-Korean study of 106 patients with LS. No survival benefit of
extended surgery was established
Parry et al.62 The authors reported a decrease in metachronous CRC risk for every 10 cm of bowel removed. The cumulative risk of
metachronous CRC in 322 patients undergoing segmental colectomy was 16 (95% c.i. 10 to 25)% at 10 years, 41 (30 to
52)% at 20 years and 62 (50 to 77)% at 30 years. Of the 50 patients who underwent extensive colonic resection (STC+ ISA
or IRA) for their first colonic cancer, none were diagnosed with metachronous CRC over 414 person-years of follow-up
Stupart et al.63
Natarajan et al.64
Other retrospective comparative studies have reported a high incidence of metachronous CRC after segmental colectomy and
a lower incidence after extended colectomy. STC with IRA or ISA decreases the risk of metachronous colonic cancer and
provides easy endoscopic surveillance
You et al.65 This study of 201 extended resections (STC+ ISA or TC+ IRA) and 321 segmental colectomies for indications other than
inflammatory bowel diseases reported a median of four daily bowel movements after ISA and five after IRA, despite
considerable dietary restrictions (reported by 55⋅6 per cent) and medication use (19⋅6 per cent reported daily use).
STC+ ISA resulted in significantly less daytime and night-time bowel movements than TC+ IRA (P = 0⋅002) but no
significant difference in quality-of-life measures (P = 0⋅16)
LS, Lynch syndrome; CRC, colorectal cancer; HNPCC, hereditary non-polyposis colorectal cancer; RR, relative risk; STC, subtotal colectomy; ISA,
ileosigmoidal anastomosis; IRA, ileorectal anastomosis; TC, total colectomy.
and path_MSH2 carriers is preferable to reduce the risk
of subsequent colorectal cancer, even though extended
surgery has not been shown to improve overall survival.
There is no substantial evidence to support extended
surgery for path_MSH6 and path_PMS2 carriers. All surgi-
cal decision-making should be personalized, based on the
patient’s age, gender, and expected functional outcome and
priorities.
Subquestion 1: should extended surgery for Lynch
syndrome-associated colonic cancer be
recommended?
A largely retrospective body of evidence supports the
extension of surgical resection in path_MLH1 and
path_MSH2 carriers, but the risk of metachronous colorec-
tal cancer in path_MSH6 and path_PMS2 carriers is not
high enough to warrant an extended approach (Table 6).
Conclusions and recommendations
• For a path_MLH1 or path_MSH2 carrier with a
first colonic cancer, extended surgery with ileosig-
moidal/ileorectal anastomosis is preferable to standard
resection to reduce the risk of metachronous colorectal
cancer.
• For a path_MSH6 or path_PMS2 pathogenic variant
carrier with a first colonic cancer, standard/segmental
colonic resection should be offered.
• For a path_MMR carrier with a metachronous colonic
cancer, the surgical treatment can be extended surgery
with ileorectal/ileosigmoidal anastomosis.
• A decision on extended surgery for colorectal cancer
should not be based on deficient MMR immunohisto-
chemistry (loss of MLH1, MSH2, MSH6 or PMS2) and
BRAF staining/MLH1 hypermethylation from the pre-
operative endoscopic biopsy only.
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Table 7 Surgical options for colorectal cancer in path_MMR carriers
Path_MLH1 Path_MSH2 Path_MSH6 Path_PMS2
Additional risk
factors
Primary colonic cancer of
a known LS pathogenic
variant carrier
Subtotal colectomy
with ileosigmoidal
(ileorectal)
anastomosis
Subtotal colectomy
with ileosigmoidal
(ileorectal)
anastomosis
Segmental colectomy
(right, extended right
or left colectomy)
Segmental colectomy
(right, extended right
or left colectomy)
Adenoma formation in
a colonic segment
other than the
segment affected by
colonic cancer
Extended surgery such
as colectomy with
ileosigmoidal or
ileorectal
anastomosis.
For young patients,
consider more
extensive surgery
Metachronous colonic
cancer in a known LS
pathogenic variant
carrier who has
undergone previous
segmental colectomy
Subtotal colectomy
with ileorectal
anastomosis
Subtotal colectomy
with ileorectal
anastomosis
Subtotal colectomy
with ileorectal
anastomosis
Subtotal colectomy
with ileorectal
anastomosis
Primary rectal cancer in a
known LS pathogenic
variant carrier
Anterior
resection/APR
Anterior
resection/APR
Anterior
resection/APR
Anterior
resection/APR
Rectal cancer after
previous colonic cancer
surgery in a known LS
pathogenic variant
carrier
Proctectomy/
proctocolectomy
with ileoanal
anastomosis with
pouch or APR with
permanent
ileostomy
Proctectomy/
proctocolectomy
with ileoanal
anastomosis with
pouch or APR with
permanent
ileostomy
Proctectomy/
proctocolectomy
with ileoanal
anastomosis with
pouch or APR with
permanent
ileostomy
LS, Lynch syndrome; APR, abdominoperineal resection.
Subquestion 2: how should surgery for rectal
cancer in Lynch syndrome be performed?
Studies have reported metachronous cancer after rectal
cancer in carriers66,67. Because the cumulative risk of a
subsequent colonic cancer developing during surveillance
is significant, extended surgery may be a personal pref-
erence, considering the higher degree of surgical mor-
bidity associated with the procedure. Quality of life of
patients with an ileoanal pouch may be comparable to
that of patients with familial adenomatous polyposis rather
than those with inflammatory bowel disease (IBD), because
the worse overall outcome in the latter group is due to
the underlying inflammatory condition. There is clear evi-
dence that surgeons performing a high volume of proce-
dures in high-volume units (over 10 per year) achieve lower
pouch failure rates as well as better pouch salvage than
those with a lower throughput of these procedures68,69.
Preferred surgical options by gene are shown in Table 7.
Conclusions and recommendations
• For a path_MMR carrier, the surgical treatment of a
primary rectal cancer (occurring as the first colorectal
cancer) should be standard resection (anterior resection
or abdominoperineal resection).
• In a young path_MMR carrier with a synchronous col-
orectal neoplasm or a personal preference, extended
surgery can be considered.
• Ileoanal pouch surgery (in agreement with European
CanCer Organisation guidelines for pouch surgery in
ulcerative colitis) should be performed in highly special-
ized colorectal surgical units.
Subquestion 3: should prophylactic bowel surgery
be performed?
It is acknowledged that, even with the more favourable
stage at diagnosis in patients under surveillance, there is
a 9 per cent overall mortality rate among patients with LS
in the 10 years after diagnosis of colorectal cancer. There is
no documented procedure to identify and separate carriers
at higher risk of colorectal cancer than the average by
using age, gene and gender, nor those who might be at
risk of not surviving a future colorectal cancer. There is no
evidence base to support prophylactic colorectal surgery in
path_MMR carriers.
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Table 8 Association studies between BMI, smoking, alcohol consumption, physical activity and colorectal cancer in Lynch syndrome
Reference Study outcomes
Diergaarde et al.73
Botma et al.74
Campbell et al75
Movahedi et al.76
Win et al.77
These studies reported on the association between BMI and colorectal tumours in LS. A high BMI was associated with an
increased risk of colorectal tumours in three publications74,76,77 another75 indicated an association in the same direction,
and one73 did not show an association
Diergaarde et al.73
Kamiza et al.78
Watson et al.79
Winkels et al.80
Dashti et al.81
In analyses of alcohol consumption and colorectal tumour risk in LS, three studies73,78,79 did not observe an association,
one80 demonstrated a possible increased risk, and one81 reported a significant increase in risk of colorectal tumours when
alcohol consumption was high
Kamiza et al.78 The influence of physical activity on colorectal tumour risk has been investigated in only one study, which showed that being
physically active is significantly associated with a decreased colorectal tumour risk in those with LS
Brand et al.82
Diergaarde et al.73
Pande et al.83
Watson et al.79
Winkels et al.80
The risk of colorectal tumours is significantly increased by smoking in LS
Diergaarde et al.73
Kamiza et al.78
Botma et al.74
Voskuil et al.84
Burn et al.85
Mathers et al.86
Jung et al.87
Chau et al.88
Heine-Bröring et al.89
Different aspects of diet, such as dietary patterns74, and consumption of meat73,78,84, vegetables73,78, fruit73,78, fish73, dairy
products73, dietary fibre73,85,86, dietary B vitamins87, dietary supplements88,89, tea73 and coffee73 have been investigated in
relation to colorectal tumour risk in people with LS. None of these dietary factors, however, were evaluated in more than
three publications
LS, Lynch syndrome.
In a study70 of patients with high-grade dysplasia in
endoscopic biopsies and a polyp that was not amenable
to endoscopic removal, 22 of 165 polyps (13⋅3 per cent)
had an invasive cancer on final pathology. In another study
at the Mayo Clinic71, 133 of 750 unresectable polyps
(17⋅7 per cent) harboured a malignancy, of which 23 per
cent were lymph node-positive. Although these studies
were conducted without knowledge of the MMR status
of the tumours, they indicate that high-grade dysplasia on
biopsy is a strong predictor of tumours harbouring invasive
malignancy.
In patients with LS and concurrent IBD, it is unclear
whether colorectal cancer risks are sufficiently increased
for prophylactic colectomy to be indicated. In a small
series72 of 12 patients with LS and concurrent IBD, four
developed colorectal cancer in an early age. However,
the series did not demonstrate a sufficiently increased
risk of colorectal cancer to recommend prophylactic
surgery.
Conclusions and recommendations
• For endoscopically non-removable polyps with
advanced histology, an oncological approach is recom-
mended, as for gene-specific treatment for carcinoma.
• Prophylactic colorectal surgery in the absence of neo-
plastic lesions in the colorectum is not recommended
for path_MMR carriers based on their pathogenic
variant-related risk only.
Question 5: what is the influence of lifestyle
factors on the development of adenoma or
colorectal cancer in Lynch syndrome?
The majority of studies showed positive associations
between BMI and smoking and colorectal cancer,
whereas some studies reported that alcohol consump-
tion was positively associated with colorectal cancer.
One study reported an inverse association between
physical activity and colorectal cancer in path_MMR
carriers (Table 8)73–89. No lifestyle factor has been demon-
strated to increase the risk of cancer specifically for
one gender, or for carriers of pathogenic variants in a
specific gene.
Conclusions and recommendations
• Path_MMR carriers should be advised that smoking and
obesity increase the risk of colorectal cancer.
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• Path_MMR carriers should be advised that alcohol con-
sumption increases the risk of colorectal cancer.
• Path_MMR carriers should be advised that physical activ-
ity reduces the risk of colorectal cancer.
Question 6: what is the role of acetylsalicylic
acid (aspirin) in the management of Lynch
syndrome?
An RCT76,85,90 showed that 600mg acetylsalicylic acid
daily for 2–4 years was well tolerated and reduced colorec-
tal cancer incidence after 5 years following initiation of the
treatment. A recently published study91 has shown that the
benefit of prevention with acetylsalicylic acid persists into
the second decade. Observational data in the general pop-
ulation suggest that lower doses may also be effective92,93.
For bodyweight above average (70 kg), a higher dose than
currently in clinical use for other indications may be
required94.
Conclusions and recommendations
• Path_MMR carriers should be advised that daily acetyl-
salicylic acid intake will reduce colorectal cancer risk.
• The recommended acetylsalicylic acid dose should be
a minimum of 75–100mg daily. This dose should be
increased for people with above-average body mass.
Final conclusion
The recommendations from the EHTG and ESCP for
identification of patients with LS, colorectal surveillance,
surgical management of colorectal cancer, lifestyle and
chemoprevention in LS that reached a consensus (at least
80 per cent) are presented here. The joint statement also
endorsed the Manchester International Consensus Group
recommendations for the management of gynaecological
cancers in LS.
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